reldesemtiv   Click here for help

GtoPdb Ligand ID: 11801

Synonyms: CK-107 | CK-2127107 | CK2127107
Compound class: Synthetic organic
Comment: Reldesemtiv (CK-2127107) is a second generation fast skeletal muscle troponin activator [1], that was designed to improve upon tirasemtiv. Reldesemtiv slows the rate of calcium release from the troponin complex, and sensitises the sarcomere to calcium which leads to increased contractility in fast skeletal muscle fibres. Like tirasemtiv, reldesemtiv was proposed to offer a therapeutic option for debilitating muscle weakness/muscle fatigue in diseases such as spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS).
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 98.2
Molecular weight 384.15
XLogP 1.1
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES FC1CC(C1)(CNc1ncc(cn1)n1ccc(c1)C(=O)N)c1ncccc1F
Isomeric SMILES C1C(CC1(CNc1ncc(cn1)n1ccc(c1)C(=O)N)c1c(cccn1)F)F
InChI InChI=1S/C19H18F2N6O/c20-13-6-19(7-13,16-15(21)2-1-4-23-16)11-26-18-24-8-14(9-25-18)27-5-3-12(10-27)17(22)28/h1-5,8-10,13H,6-7,11H2,(H2,22,28)(H,24,25,26)
InChI Key MQXWPWOCXGARRK-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Reldesemtiv (CK-2127107) was progressed to Phase 2 evaluation as a potential therapy for amyotrophic lateral sclerosis (ALS). Treatment-induced hepatic and renal abnormalities resolved after the study drug was discontinued, and there were indications of efficacy that warranted Phase 3 evaluation in NCT04944784.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03160898 A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS) Phase 2 Interventional Cytokinetics 2
NCT04944784 A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS) Phase 3 Interventional Cytokinetics 2